Analysis of Revenues
Paying user area
Try for free
McKesson Corp. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to McKesson Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
McKesson Corp., income statement, revenues
US$ in millions
Based on: 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31).
- North America pharmaceutical distribution and services
- The revenue in this segment exhibited an overall upward trend from 2011 to 2016. Starting at $105,969 million in 2011, it experienced consistent growth, peaking at $158,469 million in 2016. Notably, there was a slight decline between 2012 and 2013, decreasing from $116,279 million to $115,443 million, but the segment rebounded strongly in subsequent years.
- International pharmaceutical distribution and services
- This segment’s data begins in 2014 with a revenue of $4,848 million and shows a significant increase in 2015 to $26,358 million, followed by a decrease in 2016 to $23,497 million. The initial jump suggests either an expansion or acquisition activity starting in 2014, while the slight decline in 2016 indicates some volatility or adjustment in this market.
- Medical-Surgical distribution and services
- Revenues in this category increased steadily over the years analyzed, starting from $2,920 million in 2011 and growing to $6,033 million in 2016. The growth rate accelerated significantly from 2013 to 2014, with revenue rising from $3,611 million to $5,648 million, after which the segment experienced more moderate growth.
- Distribution Solutions
- This segment's revenue closely tracks the combined total of North America pharmaceutical distribution, International pharmaceutical distribution, and Medical-Surgical services, reflecting that it may be a consolidated category. It showed steady growth from $108,889 million in 2011 to $187,999 million in 2016, with an especially large increase between 2014 and 2015.
- Technology Solutions, products and services
- The revenue for this segment showed a slight decline over the period, decreasing from $3,195 million in 2011 to $2,885 million in 2016. There was minor fluctuation during this period, with a peak in 2013 at $3,401 million, but the overall trend was downward.
- Overall Revenues
- Total revenues exhibited consistent growth from $112,084 million in 2011 to $190,884 million in 2016, representing a substantial increase over the six-year period. The trend corresponds closely with the growth seen in Distribution Solutions, indicating the company's core business areas are driving the revenue increase. A marked acceleration occurred between 2014 and 2015, reflecting strength in both domestic and international distribution segments.